Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorder) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2021 Update

Pages: 857 Published: October 31, 2021 Report Code: GMDGDHC13117IDB

Type 1 diabetes (T1D) is an autoimmune disease in which a pancreas stops producing insulin, a hormone that enables people to get energy from food. It occurs when the body’s immune system attacks and destroys the insulin-producing cells in the pancreas, called beta cells. Risk factors of type 1 diabetes include genetics and family history, diseases of the pancreas, and infection or illness. The signs and symptoms of type 1 diabetes include increased thirst and frequent urination, extreme hunger, weight loss, fatigue, irritability, or unusual behavior.

The Type 1 Diabetes Drugs in Development market research report provides comprehensive information on the therapeutics under development for Type 1 Diabetes, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Type 1 Diabetes and features dormant and discontinued projects.

What are the targets of the Type 1 Diabetes pipeline drugs market?

Some of the targets of the Type 1 Diabetes pipeline drugs market are Insulin Receptor, Interleukin 2 Receptor, Calcitonin Receptor, Receptor Activity Modifying Protein 1, Receptor Activity Modifying Protein 2, Receptor Activity Modifying Protein 3, Gamma-Aminobutyric Acid Type A Receptor Subunit (GABA, Glucagon Receptor, Islet Amyloid Polypeptide, and Cannabinoid Receptor 1.

Type 1 Diabetes pipeline drugs market, by targets

Type 1 Diabetes pipeline drugs market, by targets

For more target insights, download a free report sample

What are the mechanisms of action of the Type 1 Diabetes pipeline drugs market?

The mechanisms of action of the Type 1 Diabetes pipeline drugs market are Insulin Receptor Agonist, Interleukin 2 Receptor Agonist, Calcitonin Receptor Agonist, Receptor Activity Modifying Protein 1 Activator, Receptor Activity Modifying Protein 2 Activator, Receptor Activity Modifying Protein 3 Activator, Gamma-Aminobutyric Acid Type A Receptor Subunit (GABAAgonist, Cannabinoid Receptor 1 Antagonist, Potassium Voltage Gated Channel Subfamily A Member 3 Blocker, and Sodium/Glucose Cotransporter 2 Inhibitor.

Type 1 Diabetes pipeline drugs market, by mechanisms of action

 Type 1 Diabetes pipeline drugs market, by mechanisms of action

For more mechanisms of action insights, download a free report sample

What are the routes of administration in the Type 1 Diabetes pipeline drugs market?

The routes of administration in the Type 1 Diabetes pipeline drugs market are subcutaneous, oral, intravenous, parenteral, intramuscular, inhalational, intradermal, intravitreal, transdermal, and buccal.

Type 1 Diabetes pipeline drugs market, by routes of administration

Type 1 Diabetes pipeline drugs market, by routes of administration

For more routes of administration insights, download a free report sample

What are the molecule types in the Type 1 Diabetes pipeline drugs market?

The molecule types in the Type 1 Diabetes pipeline drugs market are recombinant peptide, cell therapy, small molecule, monoclonal antibody, synthetic peptide, fusion protein, recombinant protein, gene therapy, gene-modified cell therapy, and vaccine.

Type 1 Diabetes pipeline drugs market, by molecule types

Type 1 Diabetes pipeline drugs market, by molecule types

For more molecule types insights, download a free report sample

Which are the key companies in the Type 1 Diabetes pipeline drugs market?

Some of the key companies in the Type 1 Diabetes pipeline drugs market are Novo Nordisk AS, Adocia SAS, Eli Lilly and Co, Akston Biosciences Corp, Biocon Ltd, Merck & Co Inc, Thermalin Inc, Diasome Pharmaceuticals Inc, Algiax Pharmaceuticals GmbH, and Arecor Therapeutics Plc.

Type 1 Diabetes pipeline drugs market, by key companies

Type 1 Diabetes pipeline drugs market, by key companies

To know more about key companies, download a free report sample

Market report scope

Targets Insulin Receptor, Interleukin 2 Receptor, Calcitonin Receptor, Receptor Activity Modifying Protein 1, Receptor Activity Modifying Protein 2, Receptor Activity Modifying Protein 3, Gamma-Aminobutyric Acid Type A Receptor Subunit (GABA, Glucagon Receptor, Islet Amyloid Polypeptide, and Cannabinoid Receptor 1
Mechanisms of Action Insulin Receptor Agonist, Interleukin 2 Receptor Agonist, Calcitonin Receptor Agonist, Receptor Activity Modifying Protein 1 Activator, Receptor Activity Modifying Protein 2 Activator, Receptor Activity Modifying Protein 3 Activator, Gamma-Aminobutyric Acid Type A Receptor Subunit (GABAAgonist, Cannabinoid Receptor 1 Antagonist, Potassium Voltage Gated Channel Subfamily A Member 3 Blocker, and Sodium/Glucose Cotransporter 2 Inhibitor
Routes of Administration Subcutaneous, Oral, Intravenous, Parenteral, Intramuscular, Inhalational, Intradermal, Intravitreal, Transdermal, and Buccal
Molecule Types Recombinant Peptide, Cell Therapy, Small Molecule, Monoclonal Antibody, Synthetic Peptide, Fusion Protein, Recombinant Protein, Gene Therapy, Gene-Modified Cell Therapy, and Vaccine
Key Companies Novo Nordisk AS, Adocia SAS, Eli Lilly and Co, Akston Biosciences Corp, Biocon Ltd, Merck & Co Inc, Thermalin Inc, Diasome Pharmaceuticals Inc, Algiax Pharmaceuticals GmbH, and Arecor Therapeutics Plc

This report provides:

  • A snapshot of the global therapeutic landscape of Type 1 Diabetes (Metabolic Disorders).
  • Reviews of pipeline therapeutics for Type 1 Diabetes (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
  • Descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • Key companies involved in Type 1 Diabetes (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • Evaluation of Type 1 Diabetes (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • All the dormant and discontinued pipeline projects.
  • Reviews of the latest news related to pipeline therapeutics for Type 1 Diabetes (Metabolic Disorders).

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Type 1 Diabetes (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Type 1 Diabetes (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understanding from the know-how what drove them from the pipeline.

Key Players

Abata Therapeutics

Adocia SAS

Aerami Therapeutics Inc

Ahead Therapeutics SL

Akston Biosciences Corp

Algiax Pharmaceuticals GmbH

Allele Biotechnology and Pharmaceuticals Inc

Alpine Immune Sciences Inc

Altheia Science SRL

ALTuCELL

Amarna Therapeutics BV

Amide Technologies Inc

AmideBio LLC

Anokion SA

Aphios Corp

Apodemus AB

APT Therapeutics Inc

Aptamer Sciences Inc

Arecor Therapeutics Plc

Ariddad Therapeutics SL

Artery Therapeutics Inc

Asake Biotechnology LLC

AstraZeneca Plc

Asylia Therapeutics Inc

AVM Biotechnology LLC

Avotres Inc

Axxam SpA

Beijing Advaccine Biotechnology Company Ltd

Beta-Cell NV

Biocon Ltd

BioLingus AG

Bioorg3.14 LLC

BioTherapeutics Inc

Biozeus Pharmaceutical SA

BirchBioMed Inc

Bol Pharma

Bopin (Shanghai) Biomedical Technology Co Ltd

Boston Therapeutics Inc

Brickell Biotech Inc

Bristol-Myers Squibb Co

BTB Pharma AB

Cancer Prevention Pharmaceuticals Inc

CAR-T (Shanghai) Biotechnology Co Ltd

Carlina Technologies SAS

Cell Source Inc

CellTrans Inc

Chongqing Chenan BioPharm Co Ltd

Code Biotherapeutics Inc

Compugen Ltd

Cour Pharmaceuticals Development Co Inc

Creative Medical Technology Holdings Inc

CRISPR Therapeutics AG

Cue Biopharma Inc

Daewoong Pharmaceutical Co Ltd

Dendright Pty Ltd

Diabetology (Products) Ltd

Diamyd Medical AB

Diasome Pharmaceuticals Inc

DiaVacs Inc

Dompe Farmaceutici SpA

Dualogics Corp

Eledon Pharmaceuticals Inc

Eli Lilly and Co

Emerald Organic Products Inc

Endsulin Inc

Ensol Biosciences Inc

Enthera Srl

EpiVax Inc

Evotec SE

Fairbanks Pharmaceuticals Inc

FasCure Therapeutics LLC

Felicitex Therapeutics Inc

Follicum AB

Gan & Lee Pharmaceuticals Co Ltd

Generex Biotechnology Corp

Genprex Inc

Geropharm

Great Bay Bio Holdings Ltd

Gubra ApS

Hanmi Pharmaceuticals Co Ltd

Housey Pharmaceutical Research Laboratories LLC

Iltoo Pharma

Imagine Pharma LLC

ImCyse SA

Immunocore Holdings Plc

ImmunoMolecular Therapeutics LLC

Immunwork Inc

ImmusanT Inc

Innovimmune Biotherapeutics Inc

Inversago Pharma Inc

Islexa Ltd

iTolerance Inc

Jaguar Gene Therapy LLC

Jiangsu Hengrui Medicine Co Ltd

Jiangsu Lianhuan Pharmaceutical Co Ltd

JN Biosciences LLC

Johnson & Johnson

Kadimastem Ltd

Kamada Pharmaceuticals

Kiniksa Pharmaceuticals Ltd

Kriya Therapeutics Inc

Kunming Yinnuo Medical Technology Co. Ltd.

L2 Diagnostics LLC

Landos Biopharma Inc

Lannett Co Inc

Larix Bioscience LLC

Lexicon Pharmaceuticals Inc

Likarda LLC

MannKind Corp

Maruho Co Ltd

Medytox Inc

Melior Pharmaceuticals I Inc

Mercia Pharma Inc

Merck & Co Inc

Metavant Sciences Ltd

MidaSol Therapeutics LP

Neovacs SA

Neurodon LLC

NexImmune Inc

NextCell Pharma AB

Novartis AG

Novo Nordisk AS

OneVax LLC

Op-T-Mune Inc

Oramed Pharmaceuticals Inc

Orgenesis Inc

Orion BioScience Inc

Orizuru Therapeutics Inc

Otsuka Holdings Co Ltd

Pancryos AS

Panorama Researchama Research

Paras Biopharmaceuticals Finland Oy

Parvus Therapeutics Inc

Pfizer Inc

PharmaCyte Biotech Inc

PolTREG Sp z o o

Polus Inc

Precigen Inc

Prometheon Pharma LLC

Protokinetix Inc

Protomer Technologies Inc

Provention Bio Inc

Purzer Pharmaceutical Co Ltd

Quell Therapeutics Ltd

Regenerative Medical Solutions Inc

REGiMMUNE Corp

Remd Biotherapeutics Inc

Remedium Bio Inc

reMYND NV

ReNeuron Group Plc

Renova Therapeutics Inc

Repertoire Immune Medicines Inc

Rezolute Inc

Rubius Therapeutics Inc

SAB Biotherapeutics Inc

Sahane Biotech Inc

Sana Biotechnology Inc

Sanofi

Sensulin LLC

Seraxis Inc

Sernova Corp

Serpin Pharma LLC

Sihuan Pharmaceutical Holdings Group Ltd

Slate Bio Inc

Sonoma Biotherapeutics Inc

SQZ Biotechnologies Co

Stelis Biopharma Pvt Ltd

SymbioCellTech LLC

Tetragenetics Inc

TherapyX Inc

Thermalin Inc

Throne Biotechnologies Inc

Toleranzia AB

Tolerion Inc

Tolerx, Inc. (Inactive)

Tonghua Dongbao Pharmaceutical Co Ltd

Topas Therapeutics GmbH

Trailhead Biosystems Inc

Transgene Biotek Ltd

TwotoBiotech Ltd

Unicyte AG

Valin Technologies Ltd

Vanilloid Genetics Inc

Ventria Bioscience Inc

Veralox Therapeutics Inc

Vertex Pharmaceuticals Inc

ViaCyte Inc

ViCapsys Inc

Virtici LLC

vTv Therapeutics Inc

Wockhardt Ltd

XERIS Pharmaceuticals Inc

XL-protein GmbH

XOMA Corp

Youngene Therapeutics Co Ltd

Zealand Pharma AS

Zucara Therapeutics Inc

Table of Contents

Table of Contents

Introduction

Type 1 Diabetes – Overview

Type 1 Diabetes – Therapeutics Development

Type 1 Diabetes – Therapeutics Assessment

Type 1 Diabetes – Companies Involved in Therapeutics Development

Type 1 Diabetes – Drug Profiles

Type 1 Diabetes – Dormant Projects

Type 1 Diabetes – Discontinued Products

Type 1 Diabetes – Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Type 1 Diabetes (Juvenile Diabetes), 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Abata Therapeutics, 2021

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Adocia SAS, 2021

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Aerami Therapeutics Inc, 2021

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Ahead Therapeutics SL, 2021

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Akston Biosciences Corp, 2021

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Algiax Pharmaceuticals GmbH, 2021

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Allele Biotechnology and Pharmaceuticals Inc, 2021

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Alpine Immune Sciences Inc, 2021

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Altheia Science SRL, 2021

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by ALTuCELL, 2021

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Amarna Therapeutics BV, 2021

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Amide Technologies Inc, 2021

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by AmideBio LLC, 2021

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Anokion SA, 2021

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Aphios Corp, 2021

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Apodemus AB, 2021

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by APT Therapeutics Inc, 2021

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Aptamer Sciences Inc, 2021

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Arecor Therapeutics Plc, 2021

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Ariddad Therapeutics SL, 2021

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Artery Therapeutics Inc, 2021

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Asake Biotechnology LLC, 2021

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by AstraZeneca Plc, 2021

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Asylia Therapeutics Inc, 2021

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by AVM Biotechnology LLC, 2021

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Avotres Inc, 2021

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Axxam SpA, 2021

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Beijing Advaccine Biotechnology Company Ltd, 2021

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Beta-Cell NV, 2021

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Medytox Inc, 2021

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Melior Pharmaceuticals I Inc, 2021

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Mercia Pharma Inc, 2021

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Merck & Co Inc, 2021

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Metavant Sciences Ltd, 2021

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by MidaSol Therapeutics LP, 2021

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Neovacs SA, 2021

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Neurodon LLC, 2021

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by NexImmune Inc, 2021

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by NextCell Pharma AB, 2021

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Novartis AG, 2021

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Novo Nordisk AS, 2021

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by OneVax LLC, 2021

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Op-T-Mune Inc, 2021

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Oramed Pharmaceuticals Inc, 2021

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Orgenesis Inc, 2021

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Orion BioScience Inc, 2021

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Orizuru Therapeutics Inc, 2021

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Otsuka Holdings Co Ltd, 2021

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Pancryos AS, 2021

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Panorama Researchama Research, 2021

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Paras Biopharmaceuticals Finland Oy, 2021

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Parvus Therapeutics Inc, 2021

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Pfizer Inc, 2021

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Veralox Therapeutics Inc, 2021

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Vertex Pharmaceuticals Inc, 2021

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by ViaCyte Inc, 2021

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by ViCapsys Inc, 2021

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Virtici LLC, 2021

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by vTv Therapeutics Inc, 2021

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Wockhardt Ltd, 2021

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by XERIS Pharmaceuticals Inc, 2021

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by XL-protein GmbH, 2021

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by XOMA Corp, 2021

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Youngene Therapeutics Co Ltd, 2021

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Zealand Pharma AS, 2021

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Zucara Therapeutics Inc, 2021

Type 1 Diabetes (Juvenile Diabetes) – Dormant Projects, 2021

Type 1 Diabetes (Juvenile Diabetes) – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Type 1 Diabetes (Juvenile Diabetes), 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Top 10 Molecule Types, 2021

Number of Products by Stage and Top 10 Molecule Types, 2021

Frequently Asked Questions

Enquire Before Buying
$2500

Can be used by individual purchaser only

$7500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.